| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3317157 | Pancreatology | 2015 | 7 Pages |
Abstract
FOLFIRINOX is feasible as neoadjuvant therapy for LAPC. Although the R0 resection rate was only 20%, the median OS of almost 3 years appears promising. Dose intensity and duration were associated with increased survival in this study, arguing against dose attenuated versions of this regimen.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Moh'd Khushman, Naomi Dempsey, Jennifer Cudris Maldonado, Arturo Loaiza-Bonilla, Michel Velez, Lauren Carcas, Daniel Dammrich, Jorge Hurtado-Cordovi, Ritesh Parajuli, Terri Pollack, Ana P. Harwood, Jessica Macintyre, Ching-Wei D. Tzeng, Jaime R. Merchan,